Microbiota as Early Diagnostic and predictivE Factor for Osteoarthritic Degeneration and Microbial Contamination

The study is a multicentre observational study divided into 3 objectives:

Objective #1 is to enrol 40 patients with established intestinal dysbiosis and no musculoskeletal symptoms. Patients with potential dysbiosis will undergo an initial (V1) gastroenterological examination at the Operative Unit of Gastroenterology and Digestive Endoscopy in Humanitas, where they will be asked to join the clinical study. Each patient will be explained the study through the means of the informed consent process, and those who wish to join the study will sign the informed consent form. For each patient, the Bristol scale will be used as a tool to categorize the patients' stool as reported by the patient; a stool sample collection kit will be provided to the patient together with its instructions for use. Patients will be instructed to provide a stool sample (V2) at the immunology and microbiota unit laboratory. On the same occasion, the clinician will perform a buccal swab to collect a saliva sample from the patient (see section 8 for specifics). Both samples will initially be stored at the Biobank - Cancer Center (Istituto Clinico Humanitas - Via Manzoni 56, 20089 Rozzano (MI)) under the responsibility of Dr. Daniela Pistillo and will then be processed at the laboratory of the immunology and microbiota unit and will be used for confirming the dysbiosis diagnosis. If the patient is not positive for dysbiosis markers, he/she will be classified as SCREENING FAILURE; if the dysbiosis is confirmed, the patient will be asked to come to another visit (V3) where he/she will undergo a MRI of the knee and a shoulder ultrasound scan in order to check for early osteoarthritis signs. Optional orthopaedic examination may be performed. Blood test will also be performed part of the samples of which will be used to evaluate biomarkers and will initially be stored at the Biobank - Cancer Center (Istituto Clinico Humanitas - Via Manzoni 56, 20089 Rozzano (MI)) with Dr. Daniela Pistillo in charge and will subsequently be processed. The other part of the blood samples on which insulin, glycated haemoglobin and glucose will be analysed will be sent to the Central Analysis Laboratory within ICH (see section 8 for details).

Objective #2 is to enrol 50 patients undergoing total knee arthroplasty (TKA). Patients scheduled to undergo TKA will undergo a pre-hospitalization orthopaedic examination (V1) where he/she will be informed about the clinical study. If he/she agrees to join the study, he/she will sign the informed consent form and will follow study procedures: questionnaires will be administered and the patient will receive a stool sample collection kit together with its instructions for use. The stool sample will be used for DNA extraction at the immunology and microbiota unit laboratory and subsequent metagenomic analysis. Patient will be instructed to hand over the stool sample during hospital visit for TKA (V2), during which intra-articular tissue samples will be collected for metagenomics. In addition, buccal swab and blood samples of the patient undergoing the surgery will be collected before surgery. Saliva, stool and blood samples for biomarkers will initially be stored at the Biobank - Cancer Center (Istituto Clinico Humanitas - Via Manzoni 56, 20089 Rozzano (MI)) under the responsibility of Dr. Daniela Pistillo and will subsequently be processed at the laboratory of the immunology and microbiota unit. The other part of the blood samples on which insulin, glycated haemoglobin and glucose will be analysed will be sent to the ICH's in-house Central Analysis Laboratory. On discharge, patient will be provided another stool collection kit. One month after surgery (V3), a follow-up examination will be performed, where patient will bring the second stool sample and will undergo another buccal swab which will also be analysed by the same laboratory (see section 8). For stool and saliva samples of V3, the storage and analysis procedure is the same as for V2. In addition, the patient will fill in the KSS questionnaires.

Objective #3 involves the enrolment of 80 patients undergoing joint revision surgery who are further divided into:

Group 1: 40 patients for septic failure of a knee or hip replacement. Group 2: 40 patients for aseptic loosening for PJI Patients will undergo a pre-hospitalization visit (V1) with orthopaedic check-up, where they will be asked to join the clinical study. Each patient will be explained the study through the means of the informed consent process, and those who wish to join the study will sign the informed consent form. Patient will be provided a stool sample collection kit for DNA extraction at the immunology and microbiota unit laboratory and subsequent metagenomic analysis. The patient will be instructed to hand over the stool sample during hospital visit for revision surgery (V2) (see section 8).

Inclusion criteria

• proven gut dysbiosis (increased Firmicutes/Bacteroidetes (F/B) phyla ratio and increased permeability); age range 18-50 years old.
• patients undergoing total knee replacement surgery
• patients undergoing joint revision surgery for septic failure of a knee or hip prostheses; patients undergoing revision surgery for aseptic mobilization for PJI

Exclusion criteria

• musculoskeletal symptoms; previous shoulder or knee surgery; previous shoulder or knee known pathological conditions; rheumatological diseases
• any concurrent or previous diseases or conditions which might negatively affect the surgery
• major predisposing factor for gut dysbiosis (antibiotic therapy in the last 6 months, BMI > 40 and inflammatory bowel disease); chronic inflammatory joint diseases (e.g., rheumatoid arthritis, psoriatic arthritis); acute (< 90 days after the index procedure) and late hematogenous (symptoms of less than three weeks duration) infections; an inadequate amount of synovial fluid (< 10 mL) for culture, WBC, and PMN (neutrophil) percentage determinations